Laboratory researchers have discovered a new antibiotic named Teixobactin that has proved to be a more potent and more effective drug against a large number of bacterial infections, that are resistant to other older and more frequently used antibiotics.
The researchers did the experiment of Teixobactin on mice infected with MRSA (methicillin-resistant Staphylococcus aureus). MRSA is a deadly bacterium which causes serious infection, which could be fatal. This new antibiotic also showed promise against the bacteria that causes pneumococcal pneumonia.
According to the researchers, the cell culture showed that Teixobactin efficiently killed drug-resistant bacteria strains of tuberculosis, Clostridium difficile, and Anthrax.
Kim Lewis, the senior author of the study, and director of the Antimicrobial Discovery Center at Northeastern University in Boston, said that researchers are currently working on the new antibiotic to make it refined and tailored for human use. He also revealed that clinical trials are set to begin in 2018.
